Sodium Glucose Co-transporter 2 (SGLT2) inhibitors
Drug Safety Update
December 2021: Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus
March 2020: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
February 2019: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum)
March 2017: SGLT2 inhibitors - updated advice on the risk of lower-limb amputation (mainly toes)
April 2016: SGLT2 inhibitors - updated advice on the risk of diabetic ketoacidosis
NICE guidance (See also drug specific links below)
NG28 Type 2 diabetes in adults: management, updated June 2022
Local Guidance
See here for local Kent & Medway diabetes prescribing guidance - includes top tips & recommendations for use of SGLT2 inhibitors (under type 2 DM)
5mg daily is the starting dose in severe hepatic impairment
| Pack |
|---|
| 28 tablet (2 x 14 tablets) |
| Pack |
|---|
| 28 tablet (2 x 14 tablets) |
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
| Pack |
|---|
| 30 tablet (3 x 10 tablets) |
| Pack |
|---|
| 30 tablet (3 x 10 tablets) |
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary